Strong controls needed for extractables and leachables says MHRA

The Medicine and Healthcare products Regulatory Agency has underscored the need for strong controls around extractables and leachables in pharmaceutical development.

Dr Melaine Pires, senior pharmaceutical assessor at the MHRA, outlined existing regulatory  guidelines to delegates at the Disposable Solutions for Biomanufacturing Conference in Munich, Germany.
Risks surrounding extractables and leachables included interfering with drug efficacy.
As such, Dr Pires said discussions were underway to harmonise legislation in key drug development regions around the world.

Author

Phill Allen

Managing Director

Phill is an innovative thinker particularly in fluid management. His expertise lies in ensuring the seamless flow of pharmaceutical liquid logistics, whether it's optimising current processes or pioneering new approaches.

Follow me